Impact of aging and comorbidities on ischemic stroke outcomes in preclinical animal models: A translational perspective.
Impact of aging and comorbidities on ischemic stroke outcomes in preclinical animal models: A translational perspective.
复制标题
DOI:
10.1016/j.expneurol.2020.113494
复制
发表时间:
2021-01
影响因子:
5.3
通讯作者:
Paul S
中科院分区:
文献类型:
--
作者:
Candelario-Jalil E;Paul S
Ischemic stroke is a highly complex and devastating neurological disease. The sudden loss of blood flow to a brain region due to an ischemic insult leads to severe damage to that area resulting in the formation of an infarcted tissue, also known as the ischemic core. This is surrounded by the peri-infarct region or penumbra that denotes the functionally impaired but potentially salvageable tissue. Thus, the penumbral tissue is the main target for the development of neuroprotective strategies to minimize the extent of ischemic brain damage by timely therapeutic intervention. Given the limitations of reperfusion therapies with recombinant tissue plasminogen activator or mechanical thrombectomy, there is high enthusiasm to combine reperfusion therapy with neuroprotective strategies to further reduce the progression of ischemic brain injury. Till date, a large number of candidate neuroprotective drugs have been identified as potential therapies based on highly promising results from studies in rodent ischemic stroke models. However, none of these interventions have shown therapeutic benefits in stroke patients in clinical trials. In this review article, we discussed the urgent need to utilize preclinical models of ischemic stroke that more accurately mimic the clinical conditions in stroke patients by incorporating aged animals and animal stroke models with comorbidities. We also outlined the recent findings that highlight the significant differences in stroke outcome between young and aged animals, and how major comorbid conditions such as hypertension, diabetes, obesity and hyperlipidemia dramatically increase the vulnerability of the brain to ischemic damage that eventually results in worse functional outcomes. It is evident from these earlier studies that including animal models of aging and comorbidities during the early stages of drug development could facilitate the identification of neuroprotective strategies with high likelihood of success in stroke clinical trials.
登录
查看更多内容
DOI:
10.1016/j.bbi.2020.02.001
发表时间:
2020-07
期刊:
Brain, behavior, and immunity
影响因子:
--
作者:
Ahnstedt H;Patrizz A;Chauhan A;Roy-O'Reilly M;Furr JW;Spychala MS;D'Aigle J;Blixt FW;Zhu L;Bravo Alegria J;McCullough LD
通讯作者:
McCullough LD
影响因子:
8.3
作者:
Bosetti F;Koenig JI;Ayata C;Back SA;Becker K;Broderick JP;Carmichael ST;Cho S;Cipolla MJ;Corbett D;Corriveau RA;Cramer SC;Ferguson AR;Finklestein SP;Ford BD;Furie KL;Hemmen TM;Iadecola C;Jakeman LB;Janis S;Jauch EC;Johnston KC;Kochanek PM;Kohn H;Lo EH;Lyden PD;Mallard C;McCullough LD;McGavern LM;Meschia JF;Moy CS;Perez-Pinzon MA;Ramadan I;Savitz SI;Schwamm LH;Steinberg GK;Stenzel-Poore MP;Tymianski M;Warach S;Wechsler LR;Zhang JH;Koroshetz W
通讯作者:
Koroshetz W
影响因子:
3.7
作者:
Bennion DM;Isenberg JD;Harmel AT;DeMars K;Dang AN;Jones CH;Pignataro ME;Graham JT;Steckelings UM;Alexander JC;Febo M;Krause EG;de Kloet AD;Candelario-Jalil E;Sumners C
通讯作者:
Sumners C
DOI:
10.1152/ajpheart.00510.2018
发表时间:
2019-08-01
影响因子:
4.8
作者:
Ahmari, Niousha;Santisteban, Monica M.;Zubcevic, Jasenka
通讯作者:
Zubcevic, Jasenka
影响因子:
48
作者:
Berge, Eivind;Salman, Rustam Al-Shahi;Ford, Gary A.
通讯作者:
Ford, Gary A.